OBJECTIVE: The objective of this registry is to establish safety and efficacy of BioMatrix, BioMatrix™-Biolimus A9™ eluting stent in diabetic population in India. BACKGROUND: Diabetes mellitus is a major predisposing factor for coronary artery disease. Prognosis for diabetic population patients presenting with coronary artery disease who undergo coronary revascularization is inferior to non diabetics and remains an independent risk factor of restenosis, need for revascularization, and overall mortality. Stent thrombosis is a potential complication of first generation, permanent polymer drug-eluting stents. Biodegradable polymer is a good relief in this era and its utility in diabetic patients will be a major advantage for them. METHODS: 334 patients with diabetes mellitus and requiring angioplasty, implanted with BioMatrix stent were followed at 1, 6, 12 and 24 months who entered in a multicenter registry in India. We analyzed the incidence of major adverse cardiac events (MACE) and stent thrombosis (ST) at 1, 6, 12 and 24 months. RESULTS: The mean age was 58.71 ± 9.2 years, 81% were males, comorbidity index was 1.6 ± 1.02, and 59.1% presented with acute coronary syndrome. The incidence of adverse event rates was: MACE 1.27%. There were no incidences of myocardial infarction (MI) and target vessel revascularization (TVR). Definite stent thrombosis occurred only in 2 patients. CONCLUSION: In this registry of diabetic population treated with BioMatrixTM-Biolimus A9TM eluting stent (BioMatrix), the reported incidence of MACE and ST were much lower than previously published results. The 1- and 2-year follow-up result supports favorable clinical outcomes of using BioMatrix stents as a suitable alternative to contemporary DES available during PCI in diabetic patients.
OBJECTIVE: The objective of this registry is to establish safety and efficacy of BioMatrix, BioMatrix™-Biolimus A9™ eluting stent in diabetic population in India. BACKGROUND:Diabetes mellitus is a major predisposing factor for coronary artery disease. Prognosis for diabetic population patients presenting with coronary artery disease who undergo coronary revascularization is inferior to non diabetics and remains an independent risk factor of restenosis, need for revascularization, and overall mortality. Stent thrombosis is a potential complication of first generation, permanent polymer drug-eluting stents. Biodegradable polymer is a good relief in this era and its utility in diabeticpatients will be a major advantage for them. METHODS: 334 patients with diabetes mellitus and requiring angioplasty, implanted with BioMatrix stent were followed at 1, 6, 12 and 24 months who entered in a multicenter registry in India. We analyzed the incidence of major adverse cardiac events (MACE) and stent thrombosis (ST) at 1, 6, 12 and 24 months. RESULTS: The mean age was 58.71 ± 9.2 years, 81% were males, comorbidity index was 1.6 ± 1.02, and 59.1% presented with acute coronary syndrome. The incidence of adverse event rates was: MACE 1.27%. There were no incidences of myocardial infarction (MI) and target vessel revascularization (TVR). Definite stent thrombosis occurred only in 2 patients. CONCLUSION: In this registry of diabetic population treated with BioMatrixTM-Biolimus A9TM eluting stent (BioMatrix), the reported incidence of MACE and ST were much lower than previously published results. The 1- and 2-year follow-up result supports favorable clinical outcomes of using BioMatrix stents as a suitable alternative to contemporary DES available during PCI in diabeticpatients.
Authors: Stephan Windecker; Patrick W Serruys; Simon Wandel; Pawel Buszman; Stanislaw Trznadel; Axel Linke; Karsten Lenk; Thomas Ischinger; Volker Klauss; Franz Eberli; Roberto Corti; William Wijns; Marie-Claude Morice; Carlo di Mario; Simon Davies; Robert-Jan van Geuns; Pedro Eerdmans; Gerrit-Anne van Es; Bernhard Meier; Peter Jüni Journal: Lancet Date: 2008-08-31 Impact factor: 79.321
Authors: Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker Journal: J Am Coll Cardiol Date: 2008-09-30 Impact factor: 24.094
Authors: A Kapur; I S Malik; J P Bagger; J R Anderson; J S Kooner; M Thomas; P Punjabi; J Mayet; T Millane; J Goedicke; K Jamrozik; M A de Belder; R J Hall; K J Beatt Journal: Am Heart J Date: 2005-01 Impact factor: 4.749
Authors: Joost Daemen; Peter Wenaweser; Keiichi Tsuchida; Linda Abrecht; Sophia Vaina; Cyrill Morger; Neville Kukreja; Peter Jüni; Georgios Sianos; Gerrit Hellige; Ron T van Domburg; Otto M Hess; Eric Boersma; Bernhard Meier; Stephan Windecker; Patrick W Serruys Journal: Lancet Date: 2007-02-24 Impact factor: 79.321
Authors: Alban Dibra; Adnan Kastrati; Julinda Mehilli; Jürgen Pache; Helmut Schühlen; Nicolas von Beckerath; Kurt Ulm; Rainer Wessely; Josef Dirschinger; Albert Schömig Journal: N Engl J Med Date: 2005-08-16 Impact factor: 91.245
Authors: Frank D Weber; Henrik Schneider; Marcus Wiemer; Thomas Pfannebecker; Ulrich Tebbe; Christian W Hamm; Jochen Senges; Steffen Schneider; Christoph A Nienaber Journal: Clin Res Cardiol Date: 2007-12-06 Impact factor: 5.460